Skip to main content
Log in

A Pharmacoepidemiological Network Model for Drug Safety Surveillance

Statins and Rhabdomyolysis

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Recent withdrawals of major drugs have highlighted the critical importance of drug safety surveillance in the postmarketing phase. Limitations of spontaneous report data have led drug safety professionals to pursue alternative postmarketing surveillance approaches based on healthcare administrative claims data. These data are typically analysed by comparing the adverse event rates associated with a drug of interest to those of a single comparable reference drug.

Objective: The aim of this study was to determine whether adverse event detection can be improved by incorporating information from multiple reference drugs. We developed a pharmacological network model that implemented this approach and evaluated its performance.

Methods: We studied whether adverse event detection can be improved by incorporating information from multiple reference drugs, and describe two approaches for doing so. The first, reported previously, combines a set of related drugs into a single reference cohort. The second is a novel pharmacoepidemiological network model, which integrates multiple pair-wise comparisons across an entire set of related drugs into a unified consensus safety score for each drug. We also implemented a single reference drug approach for comparison with both multi-drug approaches. All approaches were applied within a sequential analysis framework, incorporating new information as it became available and addressing the issue of multiple testing over time. We evaluated all these approaches using statin (HMG-CoA reductase inhibitors) safety data from a large healthcare insurer in the US covering April 2000 through March 2005.

Results: We found that both multiple reference drug approaches offer earlier detection (6–13 months) than the single reference drug approach, without triggering additional false positives.

Conclusions: Such combined approaches have the potential to be used with existing healthcare databases to improve the surveillance of therapeutics in the postmarketing phase over single-comparator methods. The proposed network approach also provides an integrated visualization framework enabling decision makers to understand the key high-level safety relationships amongst a group of related drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Table I
Table II
Fig 2
Fig 3

Similar content being viewed by others

References

  1. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002 Feb 14; 346(7): 539–40

    Article  PubMed  Google Scholar 

  2. Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ (Clin Res Ed) 2001 Aug 18; 323 (7309): 359

    Article  Google Scholar 

  3. Psaty BM, Furberg CD, Ray WA, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004 Dec 1; 292(21): 2622–31

    Article  PubMed  CAS  Google Scholar 

  4. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Mar 17; 352(11): 1092–102

    Article  PubMed  CAS  Google Scholar 

  5. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed [comment]. N Engl J Med 2006 Mar 16; 354(11): 1193

    Article  PubMed  CAS  Google Scholar 

  6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 Oct 4; 296(13): 1633–44

    Article  PubMed  CAS  Google Scholar 

  7. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 Dec 4–10; 364(9450): 2021–9

    Article  PubMed  CAS  Google Scholar 

  8. Wadman M. Experts call for active surveillance of drug safety. Nature 2007 Mar 22; 446(7134): 358–9

    Article  PubMed  CAS  Google Scholar 

  9. Strom BL. How the US drug safety system should be changed. JAMA 2006 May 3; 295(17): 2072–5

    Article  PubMed  CAS  Google Scholar 

  10. Baciu A, Stratton K, Burke SP, editors. The future of drug safety: promoting and protecting the health of the public. Institute of Medicine ad hoc Committee on the Assessment of the US Drug Safety System. Washington, DC: National Academies Press, 2006 Sep 22

    Google Scholar 

  11. Psaty BM, Burke SP. Protecting the health of the public: Institute of Medicine recommendations on drug safety. N Engl J Med 2006 Oct 26; 355(17): 1753–5

    Article  PubMed  CAS  Google Scholar 

  12. Hennessy S, Strom BL. PDUFA reauthorization: drug safety’s golden moment of opportunity? N Engl J Med 2007 Apr 26; 356(17): 1703–4

    Article  PubMed  CAS  Google Scholar 

  13. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance: lack of vigilance, lack of trust. JAMA 2004 Dec 1; 292(21): 2647–50

    Article  PubMed  CAS  Google Scholar 

  14. Hampton T. Postmarket “pharmacovigilance” program on alert for adverse events from drugs. JAMA 2007 Aug 22; 298(8): 851–2

    Article  PubMed  CAS  Google Scholar 

  15. Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 2006 Apr; 31(4): 689–99

    Article  PubMed  Google Scholar 

  16. Klein DF, O’Brien CP. Improving detection of adverse effects of marketed drugs. JAMA 2007 Jul 18; 298(3): 333–4

    Article  PubMed  CAS  Google Scholar 

  17. Platt R, Madre L, Reynolds R, et al. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 2008 Dec; 17(12): 1175–82

    Article  PubMed  Google Scholar 

  18. Tiihonen J, Lonnqvist J, Wahlbeck N et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006 Dec; 63(12): 1358–67

    Article  PubMed  CAS  Google Scholar 

  19. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004 Nov 22; 164(21): 2367–70

    Article  PubMed  Google Scholar 

  20. Brownstein JS, Sordo M, Kohane IS, et al. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE 2007; 2(9): e840

    Article  PubMed  Google Scholar 

  21. Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol 2005 Feb; 58(2): 171–4

    Article  PubMed  Google Scholar 

  22. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 Dec 1; 292(21): 2585–90

    Article  PubMed  CAS  Google Scholar 

  23. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006 Apr 17; 97(8A): 61–8C

    Article  Google Scholar 

  24. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007 Dec; 16(12): 1275–84

    Article  PubMed  Google Scholar 

  25. Kulldorff M, Davis RL, Kolczak M, et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance [online]. Available from URL: http://www.populationmedicine.org/content/docs/maxSPRTsubm.pdf [Accessed 2012 Mar 29]

  26. Brown JS, Kulldorff M, Petronis KR, et al. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations. Pharmacoepidemiol Drug Saf 2009 Mar; 18(3): 226–34

    Article  PubMed  CAS  Google Scholar 

  27. Reis BY, Kohane IS, Mandl KD. An epidemiological network model for disease outbreak detection. PLoS Medicine 2007 Jun; 4(6): e210

    Article  PubMed  Google Scholar 

  28. Reis BY, Kirby C, Hadden LE, et al. AEGIS: a robust and scalable real-time public health surveillance system. J Am Med Inform Assoc 2007 Sep-Oct; 14(5): 581–8

    Article  PubMed  Google Scholar 

  29. Reis BY, Pagano M, Mandl KD. Using temporal context to improve biosurveillance. Proc Natl Acad Sci U S A 2003 Feb 18; 100(4): 1961–5

    Article  PubMed  CAS  Google Scholar 

  30. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006 Apr 17; 97(8A): 52–60C

    Article  Google Scholar 

  31. Bays H. Statin safety: an overview and assessment of the data —2005. Am J Cardiol 2006 Apr 17; 97(8A): 6–26C

    Article  Google Scholar 

  32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83

    Article  PubMed  CAS  Google Scholar 

  33. Fisher RA. Combining independent tests of significance. Am Stat 1948; 2(5): 30

    Google Scholar 

  34. Wang J, Donnan PT, Steinke D, et al. The multiple propensity score for analysis of dose-response relationships in drug safety studies. Pharmacoepidemiol Drug Saf 2001 Mar–Apr; 10(2): 105–11

    Article  PubMed  CAS  Google Scholar 

  35. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care 2007 Oct; 45 (10 Suppl. 2): S143–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants R01 GM89731 and R01 GM085421 from the National Institute of General Medical Sciences, and grants R01 LM009879 and R01 LM007677 from the National Library of Medicine, National Institutes of Health. The funding sources had no role in the research.

Although Mark Cziraky, Marcus Wilson and Rhonda Bohn have not received any direct payment, Healthcore, Inc. conducts multiple research projects supported by various pharmaceutical companies in the area of biotech and device and government work. All other authors have no conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reis, B.Y., Olson, K.L., Tian, L. et al. A Pharmacoepidemiological Network Model for Drug Safety Surveillance. Drug Saf 35, 395–406 (2012). https://doi.org/10.2165/11596610-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11596610-000000000-00000

Keywords

Navigation